
Craig Meyers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1808012/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hypochlorous acid as a disinfectant for highâ€risk HPV: Insight into the mechanism of action. Journal of Medical Virology, 2022, 94, 3386-3393.	2.5	3
2	Assessing Non‧exual Transmission of the Human Papillomavirus (HPV): Do Our Current Cleaning Methods Work?. Journal of Medical Virology, 2022, , .	2.5	2
3	Human Papillomavirus G-Rich Regions as Potential Antiviral Drug Targets. Nucleic Acid Therapeutics, 2021, 31, 68-81.	2.0	15
4	Lowering the transmission and spread of human coronavirus. Journal of Medical Virology, 2021, 93, 1605-1612.	2.5	55
5	Rebuttal to overinterpretation of the antiviral results for human coronavirus 229EÂrelative to severe acute respiratory syndrome coronavirusâ€⊋ by Rowpar Pharmaceuticals. Journal of Medical Virology, 2021, 93, 1903-1904.	2.5	0
6	Oncogenic HPV promotes the expression of the long noncoding RNA lnc-FANCI-2 through E7 and YY1. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	31
7	A Comparative Study on Delivery of Externally Attached DNA by Papillomavirus VLPs and Pseudoviruses. Vaccines, 2021, 9, 1501.	2.1	1
8	Anti-Retroviral Protease Inhibitors Regulate Human Papillomavirus 16 Infection of Primary Oral and Cervical Epithelium. Cancers, 2020, 12, 2664.	1.7	3
9	Allobetulone rearrangement to l8αH,19βH-ursane triterpenoids with antiviral activity. Natural Product Research, 2020, , 1-11.	1.0	7
10	The ability of two chlorine dioxide chemistries to inactivate human papillomavirusâ€contaminated endocavitary ultrasound probes and nasendoscopes. Journal of Medical Virology, 2020, 92, 1298-1302.	2.5	9
11	Genome-Wide Profiling of Cervical RNA-Binding Proteins Identifies Human Papillomavirus Regulation of RNASEH2A Expression by Viral E7 and E2F1. MBio, 2019, 10, .	1.8	47
12	Tissue-Specific Gene Expression during Productive Human Papillomavirus 16 Infection of Cervical, Foreskin, and Tonsil Epithelium. Journal of Virology, 2019, 93, .	1.5	16
13	Superinfection Exclusion between Two High-Risk Human Papillomavirus Types during a Coinfection. Journal of Virology, 2018, 92, .	1.5	34
14	The Human Papillomavirus E6 Oncoprotein Targets USP15 and TRIM25 To Suppress RIG-I-Mediated Innate Immune Signaling. Journal of Virology, 2018, 92, .	1.5	97
15	Effect of Productive Human Papillomavirus 16 Infection on Global Gene Expression in Cervical Epithelium. Journal of Virology, 2018, 92, .	1.5	26
16	Microarray analysis of human keratinocytes from different anatomic sites reveals site-specific immune signaling and responses to human papillomavirus type 16 transfection. Molecular Medicine, 2018, 24, 23.	1.9	15
17	Viral DNA Replication Orientation and hnRNPs Regulate Transcription of the Human Papillomavirus 18 Late Promoter. MBio, 2017, 8, .	1.8	12
18	The use of nanoparticulates to treat breast cancer. Nanomedicine, 2017, 12, 2367-2388.	1.7	74

#	Article	IF	CITATIONS
19	Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17–36. Viruses, 2017, 9, 336.	1.5	10
20	Mutations in HPV18 E1^E4 Impact Virus Capsid Assembly, Infectivity Competence, and Maturation. Viruses, 2017, 9, 385.	1.5	8
21	UVC radiation as an effective disinfectant method to inactivate human papillomaviruses. PLoS ONE, 2017, 12, e0187377.	1.1	22
22	Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNÎ ³ - and TNFα-Mediated Antiproliferative Effects and Necroptosis. Frontiers in Immunology, 2016, 7, 496.	2.2	26
23	HPV18 DNA replication inactivates the early promoter P55 activity and prevents viral E6 expression. Virologica Sinica, 2016, 31, 437-440.	1.2	4
24	Comparison of human papillomavirus type 16 replication in tonsil and foreskin epithelia. Virology, 2016, 499, 82-90.	1.1	11
25	Susceptibility of HPV16 and 18 to high level disinfectants indicated for semiâ€critical ultrasound probes. Journal of Medical Virology, 2016, 88, 1076-1080.	2.5	39
26	The importance of infection prevention and control in medical ultrasound. Australasian Journal of Ultrasound in Medicine, 2015, 18, 96-99.	0.3	7
27	Cleavage of the HPV16 Minor Capsid Protein L2 during Virion Morphogenesis Ablates the Requirement for Cellular Furin during De Novo Infection. Viruses, 2015, 7, 5813-5830.	1.5	19
28	Papillomavirus Infectious Pathways: A Comparison of Systems. Viruses, 2015, 7, 4303-4325.	1.5	30
29	Comparisons of VLP-Based ELISA, Neutralization Assays with Native HPV, and Neutralization Assays with PsV in Detecting HPV Antibody Responses in HIV-Infected Women. Journal of AIDS & Clinical Research, 2015, 06, .	0.5	10
30	The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation. Nature Communications, 2015, 6, 6537.	5.8	64
31	Native Human Papillomavirus Production, Quantification, and Infectivity Analysis. Methods in Molecular Biology, 2015, 1249, 317-331.	0.4	16
32	Replication of Human Papillomavirus in Culture. Methods in Molecular Biology, 2015, 1249, 39-52.	0.4	8
33	CD40-Mediated Amplification of Local Immunity by Epithelial Cells Is Impaired by HPV. Journal of Investigative Dermatology, 2014, 134, 2918-2927.	0.3	13
34	Adeno-associated virus type 2 infection of nude mouse human breast cancer xenograft induces necrotic death and inhibits tumor growth. Cancer Biology and Therapy, 2014, 15, 1013-1028.	1.5	12
35	Roles for Human Papillomavirus Type 16 L1 Cysteine Residues 161, 229, and 379 in Genome Encapsidation and Capsid Stability. PLoS ONE, 2014, 9, e99488.	1.1	9
36	Susceptibility of high-risk human papillomavirus type 16 to clinical disinfectants. Journal of Antimicrobial Chemotherapy, 2014, 69, 1546-1550.	1.3	61

#	Article	IF	CITATIONS
37	microRNAs are biomarkers of oncogenic human papillomavirus infections. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4262-4267.	3.3	168
38	A risk for non-sexual transmission of human papillomavirus?. Expert Review of Anti-Infective Therapy, 2014, 12, 1165-1170.	2.0	52
39	Tumor carbohydrate antigens and strategies to develop cancer vaccines and drugs. Wuhan University Journal of Natural Sciences, 2013, 18, 1-8.	0.2	6
40	Human Papillomavirus (HPV) Upregulates the Cellular Deubiquitinase UCHL1 to Suppress the Keratinocyte's Innate Immune Response. PLoS Pathogens, 2013, 9, e1003384.	2.1	164
41	Differential Dependence on Host Cell Glycosaminoglycans for Infection of Epithelial Cells by High-Risk HPV Types. PLoS ONE, 2013, 8, e68379.	1.1	34
42	Human papillomavirus type 18 chimeras containing the L2/L1 capsid genes from evolutionarily diverse papillomavirus types generate infectious virus. Virus Research, 2011, 160, 246-255.	1.1	7
43	Construction of a Full Transcription Map of Human Papillomavirus Type 18 during Productive Viral Infection. Journal of Virology, 2011, 85, 8080-8092.	1.5	87
44	Papillomavirus capsid proteins mutually impact structure. Virology, 2011, 412, 378-383.	1.1	10
45	Adeno-associated virus type 2 infection activates caspase dependent and independent apoptosis in multiple breast cancer lines but not in normal mammary epithelial cells. Molecular Cancer, 2011, 10, 97.	7.9	11
46	Upregulation of p18Ink4c expression by oncogenic HPV E6 <i>via</i> p53â€miRâ€34a pathway. International Journal of Cancer, 2011, 129, 1362-1372.	2.3	71
47	The E7 Open Reading Frame Acts in <i>cis</i> and in <i>trans</i> To Mediate Differentiation-Dependent Activities in the Human Papillomavirus Type 16 Life Cycle. Journal of Virology, 2011, 85, 8852-8862.	1.5	42
48	Cross-Neutralization Potential of Native Human Papillomavirus N-Terminal L2 Epitopes. PLoS ONE, 2011, 6, e16405.	1.1	42
49	Human Papillomavirus Deregulates the Response of a Cellular Network Comprising of Chemotactic and Proinflammatory Genes. PLoS ONE, 2011, 6, e17848.	1.1	145
50	Differentiation-Dependent Interpentameric Disulfide Bond Stabilizes Native Human Papillomavirus Type 16. PLoS ONE, 2011, 6, e22427.	1.1	31
51	Study of infectious virus production from HPV18/16 capsid chimeras. Virology, 2010, 405, 289-299.	1.1	7
52	Downregulation of Cdc2/CDK1 Kinase Activity Induces the Synthesis of Noninfectious Human Papillomavirus Type 31b Virions in Organotypic Tissues Exposed to Benzo[<i>a</i>]pyrene. Journal of Virology, 2010, 84, 4630-4645.	1.5	14
53	Human Papillomavirus Types 16 and 18 DNA Load in Relation to Coexistence of Other Types, Particularly Those in the Same Species. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2507-2512.	1.1	28
54	Adeno-Associated Virus Type 2 Induces Apoptosis in Human Papillomavirus-Infected Cell Lines but Not in Normal Keratinocytes. Journal of Virology, 2009, 83, 10286-10292.	1.5	8

#	Article	IF	CITATIONS
55	Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. Rna, 2009, 15, 637-647.	1.6	203
56	Tissue-Spanning Redox Gradient-Dependent Assembly of Native Human Papillomavirus Type 16 Virions. Journal of Virology, 2009, 83, 10515-10526.	1.5	77
5 7	Overlapping and independent structural roles for human papillomavirus type 16 L2 conserved cysteines. Virology, 2009, 393, 295-303.	1.1	29
58	Expression Pattern and Subcellular Localization of Human Papillomavirus Minor Capsid Protein L2. American Journal of Pathology, 2009, 174, 136-143.	1.9	23
59	The Cigarette Smoke Carcinogen Benzo[<i>a</i>]pyrene Enhances Human Papillomavirus Synthesis. Journal of Virology, 2008, 82, 1053-1058.	1.5	98
60	Aberrant Expression of Oncogenic and Tumor-Suppressive MicroRNAs in Cervical Cancer Is Required for Cancer Cell Growth. PLoS ONE, 2008, 3, e2557.	1.1	610
61	Regulation of human papillomavirus type 31 late promoter activation and genome amplification by protein kinase C. Virology, 2006, 348, 328-340.	1.1	11
62	A Protease Inhibitor Specifically Inhibits Growth of HPV-Infected Keratinocytes. Molecular Therapy, 2006, 13, 1142-1148.	3.7	6
63	Adeno-Associated Virus Type 2 Increases Proteosome-Dependent Degradation of p21 WAF1 in a Human Papillomavirus Type 31b-Positive Cervical Carcinoma Line. Journal of Virology, 2006, 80, 4927-4939.	1.5	17
64	The role of the human papillomavirus type 18 E7 oncoprotein during the complete viral life cycle. Virology, 2005, 338, 61-68.	1.1	44
65	Genetic Analysis of the Human Papillomavirus Type 31 Differentiation-Dependent Late Promoter. Journal of Virology, 2005, 79, 3309-3321.	1.5	40
66	Propagation of Infectious, High-Risk HPV in Organotypic. , 2005, 119, 171-186.		33
67	Genetic and Biochemical Analysis of cis Regulatory Elements within the Keratinocyte Enhancer Region of the Human Papillomavirus Type 31 Upstream Regulatory Region during Different Stages of the Viral Life Cycle. Journal of Virology, 2004, 78, 612-629.	1.5	23
68	Evidence for the coexistence of two genital HPV types within the same host cell in vitro. Virology, 2004, 321, 173-180.	1.1	38
69	Propagation, infection, and neutralization of authentic HPV16 virus. Virology, 2004, 322, 213-219.	1.1	54
70	Comparison of the basal and glucocorticoid-inducible activities of the upstream regulatory regions of HPV18 and HPV31 in multiple epithelial cell lines. Virology, 2003, 306, 197-202.	1.1	19
71	Human papillomavirus type 45 propagation, infection, and neutralization. Virology, 2003, 312, 1-7.	1.1	54
72	Replication and interaction of herpes simplex virus and human papillomavirus in differentiating host epithelial tissue. Virology, 2003, 315, 43-55.	1.1	14

#	Article	IF	CITATIONS
73	Induction of the Upstream Regulatory Region of Human Papillomavirus Type 31 by Dexamethasone Is Differentiation Dependent. Journal of Virology, 2003, 77, 10975-10983.	1.5	7
74	The Upstream Regulatory Region of Human Papillomavirus Type 31 Is Insensitive to Glucocorticoid Induction. Journal of Virology, 2002, 76, 9702-9715.	1.5	13
75	Infectious Virions Produced from a Human Papillomavirus Type 18/16 Genomic DNA Chimera. Journal of Virology, 2002, 76, 4723-4733.	1.5	36
76	Genetic Analysis of cis Regulatory Elements within the 5′ Region of the Human Papillomavirus Type 31 Upstream Regulatory Region during Different Stages of the Viral Life Cycle. Journal of Virology, 2002, 76, 4798-4809.	1.5	23
77	Variable expression of some "housekeeping―genes during human keratinocyte differentiation. Analytical Biochemistry, 2002, 307, 341-347.	1.1	76
78	Altered Biology of Adeno-associated Virus Type 2 and Human Papillomavirus during Dual Infection of Natural Host Tissue. Virology, 2001, 287, 30-39.	1.1	42
79	Ubiquitous Human Adeno-Associated Virus Type 2 Autonomously Replicates in Differentiating Keratinocytes of a Normal Skin Model. Virology, 2000, 272, 338-346.	1.1	69
80	Two Novel Promoters in the Upstream Regulatory Region of Human Papillomavirus Type 31b Are Negatively Regulated by Epithelial Differentiation. Journal of Virology, 1999, 73, 3505-3510.	1.5	31
81	Temporal and Spatial Expression of the E5a Protein during the Differentiation-Dependent Life Cycle of Human Papillomavirus Type 31b. Virology, 1998, 248, 208-217.	1.1	32
82	Human Papillomavirus Type 31b E1 and E2 Transcript Expression Correlates with Vegetative Viral Genome Amplification. Virology, 1998, 248, 218-230.	1.1	91
83	Temporal Usage of Multiple Promoters during the Life Cycle of Human Papillomavirus Type 31b. Journal of Virology, 1998, 72, 2715-2722.	1.5	99
84	Infection and Replication of Herpes Simplex Virus Type 1 in an Organotypic Epithelial Culture System. Virology, 1997, 230, 236-243.	1.1	54
85	Organotypic (raft) epithelial tissue culture system for the differentiation-dependent replication of papillomavirus. Cytotechnology, 1996, 18, 201-210.	0.7	63